Amarin Corporation plc presented in vitro data at the European Society of Cardiology Congress 2025 on the effects of EPA on lipoprotein(a) oxidation and anti-inflammatory mechanisms of IPE. The data suggests that EPA may protect against inflammation in ASCVD by modulating the ATP–P2X7 axis and NLRP3 activation in MDMs. Additionally, EPA was found to inhibit Lp(a) oxidation and reduce oxidative stress and pro-inflammatory protein expression in endothelial cells, potentially reducing cardiovascular risk. These findings offer promising insights into the mechanisms of action for VASCEPA/VAZKEPA in cardiovascular disease management.

VASCEPA (icosapent ethyl) capsules, the first prescription treatment approved by the FDA with IPE, have shown promising results in reducing cardiovascular risk in high-risk patients with elevated Lp(a). The drug has been prescribed over twenty-five million times and has been approved in various countries worldwide. VASCEPA is indicated as an adjunct to statin therapy to reduce the risk of cardiovascular events in patients with elevated triglyceride levels and established cardiovascular disease or diabetes with additional risk factors. Important safety information includes contraindications in patients with known hypersensitivity and an increased risk of atrial fibrillation or flutter. A recent study found that patients with a history of atrial fibrillation had a higher incidence of atrial fibrillation or flutter. VASCEPA may pose a risk of allergic reactions for patients with fish or shellfish allergies. In a trial, VASCEPA was linked to a 12% risk of bleeding, especially in those taking antithrombotic medications. Common side effects included musculoskeletal pain, peripheral edema, constipation, gout, and atrial fibrillation. Patients taking VASCEPA with blood thinners should be monitored for bleeding. For more information on VASCEPA in Europe, refer to the Summary of Product Characteristics for VAZKEPA. Investors should be cautious as VASCEPA’s future success is uncertain. 1. The stock market experienced a significant drop today, with the Dow Jones Industrial Average falling by 500 points due to concerns over rising inflation and interest rates.

2. In local news, a new study shows that air pollution levels in the city have reached dangerous levels, prompting calls for stricter environmental regulations.

3. The latest data from the Labor Department indicates that unemployment rates have dropped to a record low of 3.8%, signaling a strong job market.

4. A major international trade agreement was signed today, promising to boost global economic growth and open up new markets for participating countries.

5. Researchers have discovered a new species of dinosaur in Argentina, shedding light on the ancient biodiversity of the region.

Read more at 1. Amazon reports record-breaking revenue in the third quarter, surpassing $100 billion for the first time. – Reuters

2. Tesla CEO Elon Musk sells $5 billion in company shares, causing stock price to drop. – CNBC

3. Facebook announces rebranding to Meta, focusing on the metaverse and virtual reality. – Wall Street Journal

4. Pfizer seeks FDA approval for COVID-19 vaccine booster shots for all adults. – CBS MarketWatch: Amarin Highlights Key Data Providing Mechanistic Insights